AV-001 is under clinical development by Vasomune Therapeutics and currently in Phase II for Acute Respiratory Distress Syndrome. According to GlobalData, Phase II drugs for Acute Respiratory Distress Syndrome have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AV-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AV-001 overview

AV-001 is under development for the treatment of pathogen-induced acute respiratory distress syndrome (ARDS), acute kidney injury, acute lung injury, diabetic wound healing, neuropathic diabetic foot ulcers, neuroischemic diabetic foot ulcers, asthma, atopic dermatitis, covid-19 associated acute respiratory distress syndrome, diabetic atherosclerosis, COVID-19 and metastatic disease. It is administered through intravenous bolus, parenteral route. It is a predecessor analog of vasculotide. Vasculotide is an angiogenic peptide mimetic and acts by targeting Tie-2.

Vasomune Therapeutics overview

Vasomune Therapeutics is a biotechnology company developing the next generation of medications to harness the body’s ability to defend against illness by modifying cellular response for the treatment of patients with pathogen-induced Acute Respiratory Distress Syndrome.

For a complete picture of AV-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.